Shilpa Medicare Peer Comparison

NSE: SHILPAMED | BSE: 530549

₹991.50

₹1.85 (0.19%)

As on 13-Nov-2026IST

Market cap

₹19,423 Cr

Revenue (TTM)

₹1,842 Cr

P/E Ratio

58.4

P/B Ratio

Div. Yield

0.1 %

Edit

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Market cap (₹ Cr)	19,423	18,167	18,140	17,604	15,098
Revenue (₹ Cr)	1,842	3,330	2,383	2,654	2,602
Net Profit (₹ Cr)	308.62	720.77	700.18	859.38	177.73
Net Margin (%)	16.63	21.60	27.87	30.42	6.74
RoE (%)	11.81	18.93	18.40	18.58	21.49
Price to Earnings	58.43	25.68	26.33	20.48	84.95
Price-To-Book	7.04	4.38	4.65	4.01	17.18

Income Statement (₹ Cr)

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Operating Revenue	1,841.62	3,329.63	2,383.13	2,654.29	2,602.07
Total Income	1,855.87	3,337.47	2,512.01	2,825.39	2,637.50
Total Expenditure	1,328.95	2,168.88	1,552.50	1,681.39	2,351.82
EBITDA	512.67	1,160.75	830.63	972.90	250.25
Depreciation	130.47	285.40	83.19	57.71	20.02
EBIT	382.20	875.35	747.44	915.19	230.23
Interest	49.12	187.51	0.94	8.91	6.94
Other Income	14.25	7.84	128.88	171.10	35.43
Exceptional Items	11.73	-53.14	0.00	82.90	-14.80
Profit before Tax	359.06	642.54	875.38	1,160.28	243.92
Provision for Tax	50.44	-78.23	175.20	300.90	66.19
Profit after Tax	308.62	720.77	700.18	859.38	177.73

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Shareholder's Funds	2,757.68	4,144.34	3,902.45	4,385.41	878.92
Minority Interest	0.00	-10.85	-11.18	0.00	0.00
Non-Current Liabilities	363.37	758.48	55.61	222.21	122.97
Current Liabilities	1,016.50	2,681.14	366.06	685.36	1,189.51
Total Liabilities	3,705.61	7,246.72	4,037.51	4,921.88	2,414.58

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Non-Current Assets	2,763.86	5,578.78	1,528.69	905.21	53.64
Current Assets	1,277.15	1,800.86	2,696.84	4,024.56	1,936.62
Total Assets	3,705.61	7,246.72	4,037.51	4,921.88	2,414.58
Total Debt*	657.97	2,309.68	0.57	2.50	0.00
Net Current Assets	260.65	-880.28	2,330.78	3,339.20	747.11
Contingent Liabilities	160.01	51.57	17.53	370.49	121.23

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Cash From Operating Activities	342.18	537.99	523.24	967.57	-15.14
Cash Flow from Investing Activities	-325.92	-369.46	-582.30	-561.67	18.69
Cash from Financing Activities	13.62	-313.53	-46.46	-798.31	-91.97
Net Cash Inflow / Outflow	29.88	-145.00	-105.52	-392.41	-88.42

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
ROCE (%)	11.43	14.47	24.97	23.39	31.24
ROE (%)	11.81	18.93	18.40	18.58	21.49
ROA (%)	8.09	9.78	17.77	17.36	9.34
EBIT Margin (%)	20.75	26.29	31.36	34.48	8.85
Net Margin (%)	16.63	21.60	27.87	30.42	6.74
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Revenue Growth (%)	37.26	11.06	16.84	11.75	29.70
EBIT Growth (%)	56.89	13.71	18.76	21.45	-15.90
Net Profit Growth (%)	127.86	60.98	17.44	2.39	-10.76
EPS Growth (%)	5.65	80.38	17.02	13.17	-18.93
Book Value Growth (%)	9.67	36.71	26.75	-0.34	13.51

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Price / Earnings	61.52	23.78	26.33	22.06	80.20
Price / Book Value	7.04	4.38	4.65	4.01	17.18
Dividend Yield (%)	0.06	0.00	0.34	1.95	0.60
EV/EBITDA	39.08	17.58	20.63	14.90	58.54
Market Cap (₹ Cr)	6,819.66	17,980.08	11,439.22	21,592.90	19,398.64

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Debt to Equity	0.08	0.10	0.00	0.00	0.00
Short term debt to equity ratio	0.16	0.12	0.00	0.00	--
Current Ratio	1.26	0.67	7.37	5.87	1.63
Quick Ratio	0.82	0.49	5.88	5.23	0.76
Interest Coverage	8.31	4.43	932.26	131.22	36.15

	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer	Astrazeneca Pharma
Debtors to sales (%)	29.09	18.98	37.32	9.10	10.95
Asset Turnover	0.48	0.45	0.60	0.54	1.37
Receivable days	113.81	63.88	121.68	26.06	31.88
Inventory Days	84.76	43.27	63.83	65.95	126.03
Payable days	101.94	151.85	108.28	81.01	163.79
Cash Conversion Cycle	96.62	-44.70	77.23	11.00	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.